跳至主要内容
临床试验/ISRCTN16680540
ISRCTN16680540暂停未知

HUNTER: Hepatocellular Carcinoma Expediter Network - created to define the hepatocellular carcinoma immune environment, the key mechanisms and biomarkers, and to develop the pre-clinical models needed, to deliver immunotherapy to patients with liver cancer

The Newcastle Upon Tyne Hospitals NHS Foundation Trust0 个研究点目标入组 1,500 人开始时间: 2019年12月10日最近更新:
适应症

试验速览

阶段
未知
状态
暂停
入组人数
1,500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Patients will be over 18 years of age
  • 2. The recruited patients will have primary liver cancer, secondary liver cancer or chronic liver disease
  • 3. Patients will be attending the Newcastle upon Tyne NHS Foundation Trust, or one of the collaborating centres, for consideration of liver related treatment
  • 4. The patient will be willing and able to provide written informed consent to take part in the study

排除标准

  • 1. Patients who have received previous treatment for HCC, unless recruited just prior to starting 2nd line treatment
  • 2. Patients deemed too distressed or unwell to approach about taking part in the research project
  • 3. Patients who lack capacity to give informed consent
  • 4. Patients who are not able to undertake study procedures

研究者

相似试验